OncoImmune founder on Merck acquiring the company to ramp up supply of Covid-19 drug

Pharmaceutical giant Merck said it plans to acquire privately-held OncoImmune for $425 million in cash, gaining rights to an under-the-radar drug that's shown striking results in hospitalized patients with Covid-19. Dr. Yang Liu, founder, CEO and chief scientific officer of Oncolmumune, joins "Squawk Box" to discuss the drug as well as the reason for the acquisition.
Mon, Nov 23 20207:19 AM EST